Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Anti-diabetic efficacy of KICG1338, a novel glycogen synthase kinase-3ß inhibitor, and its molecular characterization in animal models of type 2 diabetes and insulin resistance.

Anti-diabetic efficacy of KICG1338, a novel glycogen synthase kinase-3ß inhibitor, and its molecular characterization in animal models of type 2 diabetes and insulin resistance. Mol Cell Endocrinol. 2015 Jul 05; 409:1-10.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.